Chronic myeloid leukemia: Standard treatment options

American Journal of Health-System Pharmacy

Volumn 63, Issue 23 SUPPL., 2006, Pages

  Frame, David ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Antineoplastic agents; Busulfan; Combined therapy; Cytarabine; Dosage; Hydroxyurea; Imatinib; Interferon alfa; Leukemia; Mechanism of action; Resistance; Site of action; Toxicity; Transplantation

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; HYDROXYUREA; IMATINIB; PEGINTERFERON; PROTEIN KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DOSE RESPONSE; GENE MUTATION; HUMAN; LEUKEMIA RELAPSE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; STANDARD; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33751572000     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060525     Document Type: Conference Paper

References (25)

1. Neylon AJ, O'Brien SG. Diagnosis and Treatment of Chronic Myeloid Leukemia. In: Wiernik PH, Goldman JM, Dutcher JP, Kyle RA, eds. Neoplastic Diseases of the Blood. Cambridge, England: Cambridge University Press; 2003:53-69.
2. Talpaz M, Kantarjian HM, McCredie KB et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987; 69:1280-8.
3. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995; 345:1392-7.
4. Bonifazi F, de Vivo A, Rosti G et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001; 98:3074-81.
5. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994; 84:4064-77.
6. Kantarjian HM, O'Brien S, Cortes JE et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003; 97:1033-41.
7. Sokal JE, Gockerman JP, Bigner SH. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leuk Res. 1988; 12:453-8.
8. Guilhot F, Chastang C, Michallet M et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997; 337:223-9.
9. Baccarani M, Rosti G, de Vivo A et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002; 99:1527-35.
10. Gale RP, Hehlmann R, Zhang MJ et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood. 1998; 91:1810-9.
11. Petersdorf EW, Kollman C, Hurley CK et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood. 2001; 98:2922-9.
12. Yaish P, Gazit A, Gilon C et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science. 1988; 242:933-5.
13. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996; 56:100-4.
14. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994-1004.
15. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346:645-52.
16. Lahaye T, Riehm B, Berger U et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005; 103:1659-69.
17. Marin D, Kaeda J, Szydlo R et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 2005; 19:507-12.
18. Deininger MW. Management of early stage disease. Hematology Am Soc Hematol Educ Program. 2005:174-82.
19. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004; 11:35-43.
20. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293:876-80.
21. Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol. 2005; 12:33-9.
22. Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol. 2003; 40:80-2.
23. Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood. 2005; 105:2631-9.
24. Thomas J, Wang L, Clark RE et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004; 104:3739-45.
25. Yamamoto M, Kakihana K, Kurosu T et al. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005; 157:104-8.